$1.45
0.000.00%
At close: -
$1.48
0.032.07%
After Hours: 6:29 PM EDT
Comments
Loading...
Zentalis Pharma Analyst Ratings and Price Targets | NASDAQ:ZNTL | Benzinga
Zentalis Pharmaceuticals Inc has a consensus price target of $16.52 based on the ratings of 11 analysts. The high is $70 issued by Jefferies on May 19, 2023. The low is $2.2 issued by UBS on January 28, 2025. The 3 most-recent analyst ratings were released by Wedbush, HC Wainwright & Co., and HC Wainwright & Co. on March 28, 2025, March 27, 2025, and March 17, 2025, respectively. With an average price target of $8 between Wedbush, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 440.54% upside for Zentalis Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
HC Wainwright & Co.
Wells Fargo
UBS
Guggenheim
1calculated from analyst ratings
Analyst Ratings for Zentalis Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/28/2025 | Buy Now | 170.27% | Wedbush | Robert Driscoll45% | $4 → $4 | Reiterates | Neutral → Neutral | Get Alert |
| 03/27/2025 | Buy Now | 575.68% | HC Wainwright & Co. | Andrew Fein57% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/17/2025 | Buy Now | 575.68% | HC Wainwright & Co. | Andrew Fein57% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 01/30/2025 | Buy Now | 305.41% | Wells Fargo | Derek Archila60% | $8 → $6 | Maintains | Equal-Weight | Get Alert |
| 01/29/2025 | Buy Now | 575.68% | HC Wainwright & Co. | Andrew Fein57% | $20 → $10 | Maintains | Buy | Get Alert |
| 01/28/2025 | Buy Now | 48.65% | UBS | Eliana Merle47% | $5 → $2.2 | Maintains | Neutral | Get Alert |
| 11/15/2024 | Buy Now | 440.54% | Guggenheim | Michael Schmidt57% | $12 → $8 | Maintains | Buy | Get Alert |
| 11/15/2024 | Buy Now | 1251.35% | HC Wainwright & Co. | Andrew Fein57% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 1251.35% | Oppenheimer | Matthew Biegler37% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 08/12/2024 | Buy Now | 170.27% | Wedbush | Robert Driscoll45% | → $4 | Upgrade | Underperform → Neutral | Get Alert |
| 08/12/2024 | Buy Now | 1251.35% | HC Wainwright & Co. | Andrew Fein57% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | 237.84% | UBS | Eliana Merle47% | $28 → $5 | Downgrade | Buy → Neutral | Get Alert |
| 06/18/2024 | Buy Now | 508.11% | Wells Fargo | Derek Archila60% | $29 → $9 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 06/18/2024 | Buy Now | 575.68% | Stifel | Bradley Canino40% | $32 → $10 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 1251.35% | HC Wainwright & Co. | Andrew Fein57% | $40 → $20 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 1589.19% | Oppenheimer | Matthew Biegler37% | $50 → $25 | Maintains | Outperform | Get Alert |
| 06/18/2024 | Buy Now | 440.54% | Morgan Stanley | Matthew Harrison61% | $38 → $8 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 05/08/2024 | Buy Now | 2602.7% | HC Wainwright & Co. | Andrew Fein57% | $46 → $40 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 2062.16% | Stifel | Bradley Canino40% | $36 → $32 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 3008.11% | HC Wainwright & Co. | Andrew Fein57% | $46 → $46 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 913.51% | Wedbush | Robert Driscoll45% | $12 → $15 | Maintains | Neutral | Get Alert |
| 11/08/2023 | Buy Now | 710.81% | Wedbush | Robert Driscoll45% | $38 → $12 | Downgrade | Outperform → Neutral | Get Alert |
| 11/07/2023 | Buy Now | 2332.43% | Stifel | Bradley Canino40% | $44 → $36 | Maintains | Buy | Get Alert |
| 11/07/2023 | Buy Now | 2467.57% | Morgan Stanley | Matthew Harrison61% | $55 → $38 | Maintains | Overweight | Get Alert |
| 11/07/2023 | Buy Now | 3008.11% | HC Wainwright & Co. | Andrew Fein57% | $55 → $46 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | 3278.38% | Wells Fargo | Derek Archila60% | $51 → $50 | Maintains | Overweight | Get Alert |
| 08/10/2023 | Buy Now | 2467.57% | Wedbush | Robert Driscoll45% | → $38 | Reiterates | Outperform → Outperform | Get Alert |
| 08/10/2023 | Buy Now | 3616.22% | HC Wainwright & Co. | Andrew Fein57% | → $55 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2023 | Buy Now | 2467.57% | Wedbush | Robert Driscoll45% | → $38 | Reiterates | Outperform → Outperform | Get Alert |
| 06/07/2023 | Buy Now | 3278.38% | Stifel | Bradley Canino40% | $45 → $50 | Maintains | Buy | Get Alert |
| 06/02/2023 | Buy Now | 2940.54% | Stifel | Bradley Canino40% | $45 → $45 | Maintains | Buy | Get Alert |
| 05/29/2023 | Buy Now | 2940.54% | Stifel | Bradley Canino40% | $45 → $45 | Maintains | Buy | Get Alert |
| 05/26/2023 | Buy Now | 3278.38% | Oppenheimer | Matthew Biegler37% | → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 05/26/2023 | Buy Now | 2467.57% | Wedbush | Robert Driscoll45% | $31 → $38 | Maintains | Outperform | Get Alert |
| 05/26/2023 | Buy Now | 3616.22% | HC Wainwright & Co. | Andrew Fein57% | → $55 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2023 | Buy Now | 2940.54% | Stifel | Bradley Canino40% | $45 → $45 | Maintains | Buy | Get Alert |
| 05/19/2023 | Buy Now | 4629.73% | Jefferies | Biren Amin42% | $120 → $70 | Maintains | Buy | Get Alert |
| 05/15/2023 | Buy Now | 2940.54% | Stifel | Bradley Canino40% | $45 → $45 | Maintains | Buy | Get Alert |
| 05/11/2023 | Buy Now | 2940.54% | Stifel | Bradley Canino40% | $46 → $45 | Maintains | Buy | Get Alert |
| 05/11/2023 | Buy Now | 3616.22% | HC Wainwright & Co. | Andrew Fein57% | → $55 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 3278.38% | Oppenheimer | Matthew Biegler37% | → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 03/15/2023 | Buy Now | 3008.11% | Stifel | Bradley Canino40% | $55 → $46 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | 3616.22% | HC Wainwright & Co. | Andrew Fein57% | → $55 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 3616.22% | Stifel | Bradley Canino40% | $58 → $55 | Maintains | Buy | Get Alert |
| 11/14/2022 | Buy Now | 2062.16% | Wedbush | Robert Driscoll45% | $51 → $32 | Maintains | Outperform | Get Alert |
| 11/11/2022 | Buy Now | 3616.22% | Morgan Stanley | Matthew Harrison61% | $60 → $55 | Maintains | Overweight | Get Alert |
| 11/11/2022 | Buy Now | 1791.89% | Guggenheim | Michael Schmidt57% | $55 → $28 | Maintains | Buy | Get Alert |
| 11/10/2022 | Buy Now | 3278.38% | Oppenheimer | Matthew Biegler37% | $80 → $50 | Maintains | Outperform | Get Alert |
| 11/10/2022 | Buy Now | 1724.32% | SVB Leerink | Andrew Berens48% | $42 → $27 | Maintains | Outperform | Get Alert |
| 11/09/2022 | Buy Now | 3818.92% | Stifel | Bradley Canino40% | $70 → $58 | Maintains | Buy | Get Alert |
| 08/11/2022 | Buy Now | 3954.05% | Morgan Stanley | Matthew Harrison61% | $95 → $60 | Maintains | Overweight | Get Alert |
| 08/10/2022 | Buy Now | 2737.84% | SVB Leerink | Andrew Berens48% | $67 → $42 | Maintains | Outperform | Get Alert |
| 08/10/2022 | Buy Now | 3616.22% | HC Wainwright & Co. | Andrew Fein57% | $120 → $55 | Maintains | Buy | Get Alert |
| 07/29/2022 | Buy Now | 4629.73% | Stifel | Bradley Canino40% | $72 → $70 | Maintains | Buy | Get Alert |
| 07/12/2022 | Buy Now | — | Cowen & Co. | Tyler Van Buren46% | — | Initiates | → Outperform | Get Alert |
| 05/05/2022 | Buy Now | 4764.86% | Stifel | Bradley Canino40% | $74 → $72 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Zentalis Pharma (ZNTL) stock?
The latest price target for Zentalis Pharma (NASDAQ:ZNTL) was reported by Wedbush on March 28, 2025. The analyst firm set a price target for $4.00 expecting ZNTL to rise to within 12 months (a possible 170.27% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Zentalis Pharma (ZNTL)?
The latest analyst rating for Zentalis Pharma (NASDAQ:ZNTL) was provided by Wedbush, and Zentalis Pharma reiterated their neutral rating.
When was the last upgrade for Zentalis Pharma (ZNTL)?
The last upgrade for Zentalis Pharmaceuticals Inc happened on August 12, 2024 when Wedbush raised their price target to $4. Wedbush previously had an underperform for Zentalis Pharmaceuticals Inc.
When was the last downgrade for Zentalis Pharma (ZNTL)?
The last downgrade for Zentalis Pharmaceuticals Inc happened on June 20, 2024 when UBS changed their price target from $28 to $5 for Zentalis Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Zentalis Pharma (ZNTL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zentalis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zentalis Pharma was filed on March 28, 2025 so you should expect the next rating to be made available sometime around March 28, 2026.
Is the Analyst Rating Zentalis Pharma (ZNTL) correct?
While ratings are subjective and will change, the latest Zentalis Pharma (ZNTL) rating was a reiterated with a price target of $4.00 to $4.00. The current price Zentalis Pharma (ZNTL) is trading at is $1.48, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
